Saudi Pharmaceutical Industries and Medical Appliances Corporation (TADAWUL:2070)
30.80
+0.04 (0.13%)
Sep 3, 2026, 3:19 PM AST
TADAWUL:2070 Ratios and Metrics
Market cap in millions SAR. Fiscal year is January - December.
Millions SAR. Fiscal year is Jan - Dec.
Total Valuation
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 2, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 3,676 | 3,110 | 3,834 | 4,536 | 2,614 | 4,722 | |
Market Cap Growth | 12.82% | -18.87% | -15.48% | 73.55% | -44.65% | 0.38% |
Enterprise Value | 4,914 | 4,352 | 5,221 | 5,560 | 3,534 | 5,391 |
Last Close Price | 30.80 | 25.74 | 31.56 | 37.34 | 21.51 | 38.18 |
Price Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 2, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PE Ratio | 17.15 | 16.87 | 156.27 | - | - | 178.50 |
Forward PE | 16.68 | 16.16 | 29.44 | 54.19 | 62.57 | 25.66 |
PS Ratio | 2.12 | 1.82 | 2.28 | 2.74 | 1.84 | 3.24 |
PB Ratio | 1.99 | 1.77 | 2.50 | 2.99 | 1.54 | 2.37 |
P/TBV Ratio | 2.31 | 2.13 | 3.06 | 3.45 | 1.76 | 2.67 |
P/FCF Ratio | 32.19 | 16.98 | - | - | - | 451.01 |
P/OCF Ratio | 18.17 | 11.42 | - | 417.18 | - | 54.46 |
PEG Ratio | - | 3.15 | 3.15 | 3.15 | 3.15 | 3.15 |
EV Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 2, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
EV/Sales Ratio | 2.83 | 2.55 | 3.10 | 3.36 | 2.49 | 3.69 |
EV/EBITDA Ratio | 12.83 | 14.25 | 27.34 | 42.33 | - | 47.89 |
EV/EBIT Ratio | 16.32 | 19.20 | 45.00 | 93.10 | - | 164.19 |
EV/FCF Ratio | 43.03 | 23.75 | - | - | - | 514.92 |
Financial Efficiency
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 2, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Debt / Equity Ratio | 0.79 | 0.81 | 0.99 | 0.74 | 0.64 | 0.65 |
Debt / EBITDA Ratio | 4.02 | 4.58 | 7.76 | 8.24 | - | 11.11 |
Debt / FCF Ratio | 12.71 | 7.83 | - | - | - | 123.67 |
Net Debt / Equity Ratio | 0.59 | 0.60 | 0.81 | 0.56 | 0.41 | 0.20 |
Net Debt / EBITDA Ratio | 3.06 | 3.44 | 6.47 | 6.42 | -24.85 | 3.54 |
Net Debt / FCF Ratio | 9.46 | 5.73 | -3.07 | -8.79 | -3.95 | 38.09 |
Asset Turnover | 0.39 | 0.39 | 0.41 | 0.43 | 0.34 | 0.32 |
Inventory Turnover | 1.54 | 1.41 | 1.40 | 1.78 | 1.89 | 1.93 |
Quick Ratio | 1.00 | 0.88 | 0.76 | 0.85 | 0.95 | 1.20 |
Current Ratio | 1.35 | 1.28 | 1.17 | 1.35 | 1.39 | 1.50 |
Return on Equity (ROE) | 12.75% | 11.95% | 2.09% | -2.50% | -8.60% | 1.05% |
Return on Assets (ROA) | 3.93% | 3.26% | 1.77% | 0.97% | -1.63% | 0.45% |
Return on Invested Capital (ROIC) | 9.05% | 7.78% | 2.00% | -19.30% | -4.52% | 0.88% |
Return on Capital Employed (ROCE) | 10.70% | 9.00% | 5.00% | 2.40% | -4.40% | 1.20% |
Yields
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 2, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Earnings Yield | 5.83% | 5.93% | 0.64% | -1.12% | -6.32% | 0.56% |
FCF Yield | 3.11% | 5.89% | -10.49% | -2.11% | -6.79% | 0.22% |
Dividend Yield | 1.14% | 1.36% | - | - | - | 1.57% |
Payout Ratio | 19.01% | - | 11.32% | - | - | 446.47% |
Buyback Yield / Dilution | -0.00% | 0.15% | 0.08% | 0.31% | - | - |
Total Shareholder Return | 1.13% | 1.51% | 0.08% | 0.31% | - | 1.57% |